The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants
Objectives This study investigated the association between nirmatrelvir plus ritonavir (NMV-
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
[HTML][HTML] Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ. 1, BQ. 1.1., and XBB. 1.5 predominant omicron variants in three US health systems …
NR Aggarwal, LE Beaty, TD Bennett… - The Lancet Regional …, 2024 - thelancet.com
Summary Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19 …
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19 …
Nirmatrelvir or molnupiravir use and severe outcomes from omicron infections
Importance Ritonavir-boosted nirmatrelvir and molnupiravir are currently used in the US and
in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 …
in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 …
Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during the emergence of Omicron variants BA. 2/BA2. 12.1
NR Aggarwal, KC Molina, LE Beaty, TD Bennett… - Medrxiv, 2022 - medrxiv.org
ABSTRACT Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …
[HTML][HTML] Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA. 4, BA. 5 and XBB …
EV Low, MD Pathmanathan, SK Chidambaram… - International Journal of …, 2023 - Elsevier
Objective To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction …
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory …
Background Evidence evaluating real-world effectiveness of oral antivirals against Omicron
variants is lacking. Methods An unselected, territory-wide cohort of all initially non …
variants is lacking. Methods An unselected, territory-wide cohort of all initially non …
[HTML][HTML] Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during …
Background Effectiveness of oral antivirals in mild-to-moderate COVID-19 patients is
urgently needed. This retrospective cohort study aims to evaluate the clinical and virologic …
urgently needed. This retrospective cohort study aims to evaluate the clinical and virologic …
[HTML][HTML] Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk …
Background Timely evidence of the comparative effectiveness between COVID-19 therapies
in real-world settings is needed to inform clinical care. This study aimed to compare the …
in real-world settings is needed to inform clinical care. This study aimed to compare the …
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong's Omicron BA. 2 wave: an observational study
Background Real-world evidence on the effectiveness of oral antivirals in mild-to-moderate
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …
[HTML][HTML] Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA. 4 and BA. 5 in Colorado, USA: a …
NR Aggarwal, KC Molina, LE Beaty… - The Lancet Infectious …, 2023 - thelancet.com
Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …